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Highlights 
 Measurement of a single serum vitamin D metabolite provides only a limit 
perspective on vitamin D function 
 Multiple vitamin D metabolites may contribute to healthy human pregnancies 
 Vitamin D metabolites such as 3-epi-25-hydroxyvitamin D may be better markers of 
adverse events in pregnancy 
 Mathematical modelling of the vitamin D metabolome provides important new 
insights on vitamin D and human health   
 
 
 
Abstract 
Vitamin D deficiency is linked to adverse pregnancy outcomes such as pre-eclampsia (PET) 
but remains defined by serum measurement of 25-hydroxyvitamin D3 (25(OH)D3) alone. To 
identify broader changes in vitamin D metabolism during normal and PET pregnancies we 
developed a relatively simple but fully parametrised mathematical model of the vitamin D 
metabolic pathway. The data used for parametrisation were serum vitamin D metabolites 
analysed for a cross-sectional group of women (n=88); including normal pregnant women at 
1st (NP1, n=25) and 3rd trimester (NP3, n=21) and pregnant women with PET (n=22), as 
well as non-pregnant female controls (n=20). To account for the effects various metabolites 
have upon each other, data were analysed using an ordinary differential equation model of 
the vitamin D reaction network. Information obtained from the model was then also applied 
to serum vitamin D metabolome data (n=50) obtained from a 2nd trimester pregnancy 
cohort, of which 25 prospectively developed PET. 
Statistical analysis of the data alone showed no significant difference between NP3 and PET 
for serum 25(OH)D3 and 24,25(OH)2D3 concentrations. Conversely, a statistical analysis 
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informed by the reaction network model revealed that a better indicator of PET is the ratios 
of vitamin D metabolites in late pregnancy.  Assessing the potential predicative value, no 
significant difference between NP3 and PET cases at 15 weeks gestation was found. 
Mathematical modelling offers a novel strategy for defining the impact of vitamin D 
metabolism on human health. This is particularly relevant within the context of pregnancy, 
where major changes in vitamin D metabolism occur across gestation, and dysregulated 
metabolism is evidenced in women with established PET. 
 
Key words: Vitamin D; pregnancy; preeclampsia; metabolome; mathematical model;  
1. Introduction 
Sub-optimal serum levels of 25-hydroxyvitamin D3 (25(OH)D3) appear to be particularly 
prevalent in pregnant women [1, 2], prompting association studies linking maternal 
25(OH)D3 status and adverse events of pregnancy[3]. These include pre-eclampsia (PET) 
[4-6], small for gestational age babies [7], bacterial vaginosis [8], and gestational diabetes 
mellitus[9, 10]. However, in recent years a much broader role for vitamin D in human 
pregnancy has been proposed, incorporating effects on female reproductive health [11, 12], 
male reproductive health [11, 13], fetal development [14, 15], fetal programming [16], and 
offspring health [17, 18]. In humans, vitamin D supplementation of pregnant women has 
been carried out to investigate effects on preterm birth [19] and neonatal health [18]. 
 
It is still unclear whether vitamin D-deficiency during pregnancy is simply a manifestation of 
the broader prevalence of low vitamin D status in populations across the globe, or whether 
this reflects a normal physiological drop in 25(OH)D3 concentrations during pregnancy, or if 
pregnancy is a stress test which can exacerbate and unmask pathological vitamin D 
deficiency. Whatever the case, it is important to recognise that, to date, studies have relied 
on measurement of a single parameter to define optimal vitamin D in pregnancy – namely 
serum levels of 25(OH)D3, the major circulating form of vitamin D. We have hypothesized 
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that measurement of total serum concentrations of 25(OH)D3 alone provides only a limited 
view of vitamin D status, particularly in pregnancy where significant changes in vitamin D 
physiology occur from early gestation [20]. This includes changes in the serum carrier 
vitamin D binding protein (DBP) during pregnancy [21] which may influence the 
bioavailability of unbound or DBP-bound 25(OH)D3 [22]. 
 
During pregnancy there is also a dramatic rise in maternal circulating concentrations of the 
active hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D3) from the 1st 
trimester of gestation [23]. Thus, the impact of vitamin D during pregnancy may be better 
defined by analysis of multiple serum vitamin D metabolites – the vitamin D metabolome. In 
women with PET we have previously reported significant dysregulation of multiple vitamin D 
metabolic pathways in the 3rd trimester of pregnancy, with decreased serum 1,25(OH)2D3 
levels and enhanced catabolic 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) and 3-epi-
25(OH)D3 concentrations observed for women with PET [20]. Conversely, in a study of 
pregnant women in the 1st trimester of pregnancy who subsequently progressed to normal or 
PET pregnancies we did not observe any significant variations in serum vitamin D 
metabolites between normal and PET pregnancies [24]. The aim of the current study was to 
develop a mathematical model of the serum vitamin D metabolome to provide an improved 
statistical analysis for screening for adverse events in pregnancy, such as PET, by 
identifying markers of vitamin D function and disease based on analysis of multiple vitamin D 
metabolites. Specifically, we aimed to detect a signal within vitamin D metabolite data 
recorded both in early (1st trimester) and late (3rd trimester) pregnancy, to allow classification 
of cases into high and low risk of PET.  The study found that, rather than considering 
individual metabolite levels, inspection of specific ratios of these metabolites (as determined 
by the mathematical model) was a more informative predictive measure. Implementing data 
from a larger cohort of patients will transform this study from proof of concept into a strong 
predictive screening tool for PET. Though we have utilised data specifically with pregnancy 
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in mind, the approach presented provides a novel analytical tool for the study of vitamin D 
metabolites more generally in human health and disease.  
 
2. Materials and methods 
2.1 Human pregnancy vitamin D metabolite datasets  
Serum vitamin D metabolite data obtained from two distinct sets of pregnant women was 
utilised to ascertain the accuracy of each statistical approach (one considering individual 
metabolite levels, the other their ratios). The first group of women were from a cross-
sectional pregnancy study which included 3 groups of pregnant women booked in the West 
Midlands, UK (i) first trimester uncomplicated pregnancies (8-13 weeks) (NP1; n=25), (ii) 
healthy 3rd trimester pregnancies (>37 weeks) (NP3; n=21) and (iii) third trimester 
pregnancies complicated by PET (PET; n=22). A healthy non-pregnant female ‘control’ 
group (n=20) was also recruited for comparative serum vitamin D analysis as described in 
detail previously (West Midlands, Edgbaston REC (14/WM/1146 RG_14-194 [09.12.2016 
approval]) (Table 1) [20].  
 
For the second group of pregnant women, serum samples were purchased from the SCOPE 
(Screening for Pregnancy Endpoints) Ireland  study (n=50) (Clinical Research Ethics 
Committee of the Cork Teaching Hospital: ECM5 (10) [05.02.08 approval]) [24]. As 
previously described, sera samples from n=50 low-risk nulliparous pregnant women taken at 
15 weeks gestation (2nd trimester) were analysed. Of these, n= 25 prospectively developed 
PET and n=25 were selected as normotensive controls matched for maternal age, ethnicity 
and body mass index (BMI) (Table 1) [24]. Vitamin D metabolites were extracted from serum 
for LC-MS/MS analysis and measured as described previously [20, 24, 25]. Serum 
concentrations were obtained as outlined in Supplemental Table 1 and Supplemental 
Table 2. 
 
2.2 Analysis of serum vitamin D metabolites 
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Analysis of serum concentrations of vitamin D metabolites (25(OH)D3, 3-epi-25(OH)D3, 
1,25(OH)2D3 and 24,25(OH)2D3) was performed using previously reported liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) methods [20, 25]. In brief, 
samples were prepared for analysis by protein precipitation and supported liquid-liquid 
extraction. Analysis of serum was performed on a Waters ACQUITY ultra performance liquid 
chromatography coupled to a Waters Xevo TQ-S mass spectrometer. The LC-MS/MS 
method was validated based on US Food and Drug Administration guidelines for analysis of 
these metabolites, with CVs for each vitamin D metabolite analysis is shown in Table 2. 
 
 
 
Table 1. Demographic summary and analysis of participants in West Midlands and 
SCOPE women analysed in this study. The West Midlands group includes non-pregnant 
female controls, normal pregnant women (n=20) at first (NP1, n=25) and third trimester 
(NP3, n=21) and women with PET (n=22). The SCOPE group includes PET cases (n=25) 
matched to normotensive controls (n=25) for age, ethnicity and body mass index (BMI). 
Total frequency (n) with percentage of total group (%), and median values with 25th-75th 
interquartile range (IQR) values were calculated as stated. Statistically significant variations 
and post hoc test analyses are summarised; A ANOVA; T T-test * p<0.05, ** p<0.01, *** 
p<0.001, **** p< 0.0001. 
  West Midlands  SCOPE 
 
Non-
pregnant  
NP1  NP3  PET  Post-hoc  
analysis 
Normotensive 
controls 
PET cases 
(n=20) (n=25) (n=21) (n=22) (n=25) (n=25) 
Parity: nulliparous, 
total (%); 
multiparous, total 
(%) 
- - 
3 
(14.3%); 
18 
(81.8%); 
- 
25 (100.0%) 25 (100.0%) 
18 
(85.7%) 
4 
(18.2%)   
Maternal age,  
mean; SD, year 
36 27.8 33.6 28.1 
A Non-
pregnant & 
NP1 (**); 
Non-
pregnant & 
PET (*) 
30.5 30.5 
13.5 7.3 3.8 7.3 3.4 3.7 
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BMI, mean; SD, 
unit 
- 
27.8 28 27.8 
ns 
30.4 30.5 
8.1 5.1 6.1 3.4 3.7 
Mean arterial 
blood pressure 
(MABP), mean; 
SD, unit 
- 
88.2 85.3 111.9 
A NP1 & 
PET (****); 
NP3 & 
PET (****) 
92.2 119.7****  
9.3 8.2 9 5.4 9.5 
Vitamin D 
supplements/day 
(400iu), total (%) 
0 (0%) - 
7 
(33.3%) 
1 
(4.55%) 
ns 9 (36.0) 3 (12.0) 
Positive smoking 
status, total (%)  
0 (0%) - 0 (0%) 2 (9.1%) ns 2 (8.0) 4 (16.0%) 
Gestational age 
at delivery,  
mean; SD, week 
- 
10.1 39 36.7 
ns 
40.4 38.0 **** 
1.7 0.7 3.9 1 2.2 
Birthweight, 
mean; SD, grams 
- 
 
3521 2710 T NP3 & 
PET (**) 
3717 3109 ** 
397 1121 522.9 802 
 
Table 2. Accuracy and precision data for vitamin D metabolite analyses. Intra-day 
precision was calculated based on %RSD following the analysis of six replicates for each of 
the three concentration levels of each metabolite. Inter-day precision was performed over 
three days calculated based on %RSD following the analysis of six replicates for each of the 
three concentration levels of each metabolite per day for three days. Accuracy represents 
the percentage deviation from the true value and was calculated based on the analysis of six 
replicates of each concentration level for each metabolite. 
 
Compound 
 
Concentration 
(ng/mL) 
 
Level 
   Precision (% RSD) 
Intra-day Inter-day Accuracy (%) 
25OHD3 
0.500 Low 7.61 9.20 100.15 
5.00 Medium 10.68 7.45 91.34 
 20.00 High 4.18 4.93 106.84 
      
3-Epi-25OHD3 
0.188 Low 8.38 11.61 103.83 
1.875 Medium 8.41 6.10 111.74 
 7.500 High 3.20 5.25 97.45 
      
1α,25(OH)2D3 
0.061 Low 9.64 8.20 111.80 
0.750 Medium 3.05 5.30 99.33 
 2.000 High 4.29 4.20 99.96 
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23R,25(OH)2D3 
1.00 Low 6.46 9.62 98.02 
4.00 Medium 9.31 9.17 98.56 
 8.00 High 4.49 10.85 96.71 
      
24R,25(OH)2D3 
0.500 Low 6.19 8.13 98.62 
4.00 Medium 7.22 8.26 98.47 
 8.00 High 6.08 8.48 100.40 
      
25OHD2 
1.000 Low 10.59 9.58 96.47 
2.500 Medium 9.52 8.38 92.91 
 10.00 High 14.19 9.80 99.13 
      
24OHD2 
0.625 Low 9.26 7.07 99.11 
1.000 Medium 7.46 6.86 108.03 
 2.500 High 3.37 5.65 90.77 
      
3-Epi-25OHD2 
0.500 Low 11.11 8.20 114.80 
1.875 Medium 3.75 6.62 110.89 
 7.500 High 0.69 3.15 100.98 
      
1α,25(OH)2D2 
0.075 Low 10.44 7.88 90.44 
0.750 Medium 4.08 7.60 93.19 
 2.000 High 5.34 3.63 102.87 
      
1α,24(OH)2D2 
0.0630 Low 8.45 10.91 96.30 
0.625 Medium 4.24 5.96 102.41 
 2.000 High 4.10 5.20 109.39 
      
7αC4 
0.375 Low 5.54 8.00 106.13 
3.750 Medium 9.81 8.71 96.07 
15.00 High 7.85 8.20 98.55 
 
 
2.3  Regression analysis of vitamin D metabolite data across pregnancy  
Serum vitamin D metabolite data from the West Midlands healthy pregnant (NP1 and NP3) 
and non-pregnant cohorts were first assessed by (linear) robust regression analysis to 
estimate the relationship between metabolome concentrations and gestation progression. 
This was performed using iteratively reweighted least squares with a bi-square weighting 
function using the MATLAB Curve Fitting Toolbox [26]. Robust regression using iterative re-
weighting and non-standard weighting functions was chosen in favour to the more standard 
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linear least-squares regression due to its capabilities to reliably handle outliers present in the 
raw data. 
 
2.4 Principal component analysis 
We began by applying a standard statistical analysis to the data independent of the 
mathematical model. We examined serum vitamin D metabolites for PET and healthy patient 
serum data from the SCOPE data for all patients where all five metabolites were available 
(N=16 cases and N=22 controls). Each metabolite value was normalised by multiplying by a 
scaling factor such that the mean for each normalised metabolite became equal to one. We 
then ran a principal component analysis (PCA) on the normalised dataset using the MATLAB 
‘PCA’ function.  
 
2.5 Linear classification analysis 
The task of statistically classifying metabolite data into groups of healthy normotensive and 
PET women in an interpretable manner can be conveniently carried out using linear support-
vector machines (SVMs) [26, 27]. In this approach we find, given the training data, the best 
decision function which maps data to one of the two possible outcomes (healthy versus PET 
in our case) based on a linear combination of various features of the data, e.g. 
concentrations of different vitamin D metabolites. Using SVMs we can select the best 
possible linear decision function in terms of the accuracy of its predictions. 
   
2.6  Kinetic mathematical model of vitamin D function  
To account for the effects that vitamin D metabolites have on each other, initially the full 
chemical reaction network was modelled as a system of ordinary differential equations (in 
the next section this was reduced to a simpler but equally informative model that can be fully 
parametrised). As outlined in Table 3 and Figure 1, variables were used to design a 
mathematical kinetic model for vitamin D physiology that incorporated the main cellular 
features of vitamin D metabolism and function; active, inactive and epimerised forms of 
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vitamin D, as well as the key catabolic enzyme 24-hydroxylase. These cellular variables 
were then used as a basis to model circulating vitamin D metabolites. 
 
 
 
 
 
 
 
 
 
Table 3. Metabolite variables used in the full vitamin D kinetic model. Summary of the 
vitamin D metabolites and enzymes utilised in the full kinetic model with their abbreviation, 
functional description and measurement status included. 
 
Metabolite/ enzyme variable Abbreviation Description Measured 
25-hydroxyvitamin D3 25(OH)D3 storage pro-
hormone vitamin D 
✓ 
1,25-dihydroxyvitamin D3 1,25(OH)2D3 active vitamin D ✓ 
24,25 dihydroxyvitamin D3 24,25(OH)2D3 inactive vitamin D ✓ 
C3-epimer 25-hydroxyvitamin D3 3-epi-25(OH)D3 epimer of pro-
hormone vitamin D 
✓ 
C3-epimer 1,25-hydroxyvitamin D3 3-epi-
1α,25(OH)2D3 
epimer of active 
vitamin D 
✗ 
vitamin D-24-hydroxylase 24-hydroxylase  catabolic enzyme ✗ 
 
The metabolite network for vitamin D (Figure 1) was mathematically interrogated by 
constructing a set of ordinary differential equations (ODEs), depicted in Table 4 and Table 5, 
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describing the time-dependent behaviour of vitamin D metabolites in the metabolite network. 
Based on saturation kinetics for vitamin D metabolism [28], we assumed that the conversion 
of 25(OH)D3 to 1,25(OH)2D3 follows Michaelis-Menten kinetics. For simplicity, and to 
facilitate model parametrisation, all other reactions were assumed to obey mass action 
kinetics (i.e. either they do not saturate or they do not saturate at the levels present in our 
data).  
 
 
Figure 1: Network diagram for the kinetic model of vitamin D metabolism.  
Reaction network structure for vitamin D metabolome model, including the metabolites 25-
hydroxyvitamin D3 (25(OH)D3); C3-epimer hydroxyvitamin D3 (3-epi-25(OH)D3); 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3); 24,25-dihydroxyvitamin D3 (24,25(OH)2D3); C3-epimer 
1,25-hydroxyvitamin D3 (3-epi-1α,25(OH)2D3); and the key enzyme vitamin D-24-
hydroxylase (24-hydroxylase). Black arrows depict conversion steps and dotted lines 
indicate enzymatic interactions, numbers are defined in Table 4. Serum data was only 
available for the metabolites in red. 
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Table 4. Reaction rate terms for the full kinetic model of vitamin D metabolism shown 
in Figure 1. Reaction numbers correspond to Figure 1. Metabolites and enzymes with 
abbreviations are shown in Table 3.  Vitamin D metabolite concentrations and the Michaelis 
constant  are measured in nM. Non-catalytic rate constants ( - ) and catalytic rate 
constants ( ) are measured in d-1 and nM-1•d-1 respectively (d = days). Base production 
constants (  and ) and maximal enzyme rate  are measured in nM•d-1. 
Reaction  Description Rate term 
1 Production of 25(OH)D3 from diet and 
sunlight 
 
2 Conversion by 1α-hydroxylase of 
25(OH)D3 to 1,25(OH)2D3 
 
3 Epimerisation of 25(OH)D3 to 3-epi-
25(OH)D3 
 
4 Enzymatic conversion by 24-
hydroxylase of 25(OH)D3 to 
24,25(OH)2D3 
 
5 Degradation of 25(OH)D3  
6 Conversion of 24,25(OH)2D3 to 
calcitronic acid  
 
7 Enzymatic conversion by 24-
hydroxylase of 1,25(OH)2D3 to 
calcitroic acid 
 
8 Conversion by 1α-hydroxylase of 3-epi-  
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25(OH)D3 into 3-epi-1α,25(OH)2D3 
9 Vitamin D Receptor (VDR) activation   
10 Epimerisation of 1,25(OH)2D3 to 3-epi-
1α,25(OH)2D3 
 
11 Vitamin D Receptor (VDR) activation  
12 Enzyme production stimulated by 
1,25(OH)2D3 
 
13 Basal enzyme production 
 
14 Degradation of enzyme  
 
Table 5. Kinetic equations representing the vitamin D metabolism model network 
depicted in Figure 1. Reaction terms  for  correspond to the respective rate 
terms as given in Table 4. Variables whose concentrations are tracked in the model are 
concentrations of the vitamin D metabolites 25-hydroxyvitamin D3 (25(OH)D); C3-epimer 25-
hydroxyvitamin D3 (3-epi-25(OH)D); 1,25-dihydroxyvitamin D3 (1,25(OH)2D); 24,25-
dihydroxyvitamin D3 (24,25(OH)2D); C3-epimer 1,25-hydroxyvitamin D3 (3-epi-
1α,25(OH)2D); and the enzyme vitamin D-24-hydroxylase (24-hydroxylase).   
 
2.7 A reduced mathematical model of vitamin D function 
As shown in Table 3, serum concentrations of 3-epi-1α,25(OH)2D3 and 24-hydroxylase 
enzyme activity were not measured in the current study. A reduced mathematical model of 
vitamin D metabolism was therefore designed by applying simplifying assumptions into the 
complete model given in Table 5, incorporating solely 25(OH)D3; 1,25(OH)2D3; 
d[25(OH)D3]/dt  
d[1,25(OH)2D3]/dt  
d[24,25(OH)2D3]/dt  
d[3epi-25(OH)D3]/dt  
d[3epi-1,25(OH)2D3]/dt  
d[24-hydroxylase]/dt  
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24,25(OH)2D3 and 3-epi-25(OH)D3; and their effective mutual interactions (Figure 2). 
Firstly, we assume that levels of 24-hydroxylase are relatively constant so that we can 
assume conversion of 25(OH)D3 into 24,25(OH)2D3 and loss of 1,25(OH)2D3 from the 
system occur at a constant rate. Secondly, as we have no information regarding 3-epi-
1α,25(OH)2D3, we can simply consider loss of 3-epi-25(OH)D3 and 1,25(OH)2D3 from the 
system to also capture their loss through conversion into 3-epi-1α,25(OH)2D3. Thus, these 
simplifying assumptions (that have the benefit of facilitating complete model 
parameterisation) should not have any untoward effect on overall data.  The resulting 
reduced network has 8 unknown reaction constants and kinetic rate equations (see Table 6 
and Table 7) and can be described by a system of four ODEs (see Table 7). The equations 
can be fully parameterised (see Supplementary Information), and the steady states readily 
obtained (Table 8). These steady states are used to inform the statistical analysis in Section 
3.4. 
 
Figure 2: Network diagram of the reduced kinetic model for vitamin D metabolism. The 
network only contains chemicals with measured concentrations, 25-hydroxyvitamin D3 
(25(OH)D3); C3-epimer 25-hydroxyvitamin D3 (3-epi-25(OH)D3); 1,25-dihydroxyvitamin D3 
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(1,25(OH)2D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3). Black arrows depict 
conversion steps, and their numbers are defined in Table 6.  
 
 
 
 
 
 
Table 6. Kinetic rate terms for the reduced kinetic model of vitamin D metabolism in 
Figure 2. Reaction numbers correspond to numbered interactions as shown in Figure 2. 
Metabolites are listed with abbreviations in Table 3. Concentrations and Michaelis constant  
 are measured in nM. Non-catalytic rate constants ( - ) are measured in d-1. Base 
production constants (P25(OH)D3)  and maximal enzyme rate  are measured in  nM•d
-1. 
Reaction Description Rate term 
1 Production of 25(OH)D3 from diet 
and sunlight 
 
2 Conversion by 1α-hydroxylase of 
25(OH)D3 to 1,25(OH)2D3 
 
3 Epimerisation of 25(OH)D3 to 3-epi-
25(OH)D3 
 
4 Conversion by 24-hydroxylase of 
25(OH)D3 to 24,25(OH)2D3 
 
5 Degradation of 25(OH)D3  
6 Enzymatic conversion of 
24,25(OH)2D3 to calcitroic acid 
 
7 Effective degradation of 
1,25(OH)2D3 
 
8 Effective degradation of 3-epi-
25(OH)D3 
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Table 7. Kinetic equations for the reduced vitamin D metabolism model network 
depicted in Figure 2. Reaction terms  for correspond to the respective rate 
equations as depicted in Table 6.  Concentrations are for the vitamin D metabolites 25-
hydroxyvitamin D3 (25(OH)D3); C3-epimer 25-hydroxyvitamin D3 (3-epi-25(OH)D3); 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) and 24,25-dihydroxyvitamin D3 (24,25(OH)2D3). 
 
 
 
 
 
 
Table 8. Steady-state equations for reduced kinetic model of vitamin D metabolism. 
Relationships between metabolite concentrations at steady-state for the reduced kinetic 
model of vitamin D metabolism, depicted in Figure 2 are shown. Metabolites are listed with 
abbreviations in Table 3. Reaction parameters ( ) as defined in the rate 
equations in Table 6. Concentrations and Michaelis constant  are measured in nM. Non-
catalytic rate constants ( - ) are measured in d-1. Base production constants (  
and maximal enzyme rate  are measured in nM•d-1. 
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(3.1a) 
 
(3.1b) 
 
(3.1c) 
 
(3.1d) 
 
 
3.  Results 
3.1. Regression analysis of vitamin D metabolite data across pregnancy 
Consistent with previous single metabolite data [24], regression analysis of data from the 
first group of pregnant women (West Midlands) showed increased serum concentrations of 
1,25(OH)2D3 across normal pregnancy, but also revealed trends towards increased 
concentrations of 25(OH)D3, 3-epi-25(OH)D3, and 24,25(OH)2D3 from 1st to 3rd trimester 
(Figure 3). Data for women with PET were not included in the regression analysis but are 
shown for reference, providing further evidence for dysregulation of vitamin D metabolism in 
PET relative to healthy 3rd trimester pregnancies.   
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Figure 3: Regression analysis of serum vitamin D metabolites across normal 
pregnancy. Serum concentrations of 25-hydroxyvitamin D3 (25(OH)D3), C3-epimer 25-
hydroxyvitamin D3 (3-epi-25(OH)D3), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 24,25-
dihydroxyvitamin D3 (24,25(OH)2D3) according to week of pregnancy. Grey areas show the 
95% confidence bands around fitted regression lines (black lines solid lines) and R2 values 
for each regression are reported under their respective graphs. PET samples (3rd trimester) 
were not included in the regression but are shown for reference. 
 
3.2. Principal Component Analysis (PCA)  
Using strategies outlined in Section 2.4, PCA analysis was carried out to further interrogate 
serum vitamin D metabolite data from the West Midlands group. The first two components 
(PCA1 and PCA2) explained 74% of data variance but did not appear to separate PET and 
healthy 3rd trimester pregnancies (Supplemental Figure 1). It was possible that another 
classifier could distinguish the normal and PET groups based on the remaining variation, or 
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that a non-linear projection was required. To investigate these possibilities, we ran multiple 
classification algorithms using the MATLAB Classification Toolbox [32], however no strong 
classifiers were identified.  We therefore utilised to two linear classifier analyses: one 
independent from the mathematical model and one informed by the mathematical model. 
 
3.3 Strategy 1: Linear classifier analysis of metabolite data 
Using data from the West Midlands group and 2nd trimester data from the SCOPE group we 
investigated a possible linear classifier strategy for defining normal healthy and PET 
pregnancies based on serum vitamin D metabolites. This approach aimed to delineate 
control/ healthy normotensive and case/ PET pregnant women by using a data dividing 
plane, as illustrated in Figure 4. The dividing plane found is the best possible given the data 
in this study. A one-dimensional linear classifier specifies a single criterion for a single 
metabolite to predict whether the data represents control or case. A two-dimensional 
classifier, as illustrated in Figure 4, sets combined criterion for two metabolites. For 
example, the threshold for 3-epi-25(OH)D3 increases as 25(OH)D3 increases and vice 
versa. For a combination of more than two metabolites the linear classifier generalises to 
provide a criterion based on the combined metabolite data. The efficacy of the linear 
classifiers is determined by the accuracy of the classification (percentage of correct 
classifications on the data set). Only classifiers achieving significantly > than 50% accuracy 
were of interest.  
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Figure 4: A two-dimensional linear classifier (dotted line) incorporating serum 3-epi-
25(OH)D3 (y-axis) and 25(OH)D3 [nM] (x-axis) concentrations for the SCOPE (15 
weeks of pregnancy) (left) and West Midlands (third trimester) data (right). The linear 
classifier classes serum data in the grey section as PET case and the remainder as being 
healthy pregnancies. False-positives and false-negatives are clearly visible and lead to a 
classification accuracy of only 56% (left) and 68% (right). 
 
From earlier work [24] we postulated that individual vitamin D metabolite data cannot 
accurately predict future risk of PET onset. As shown in Figure 4, individual metabolite 
classifiers did not reach accuracies > 68%. However, combining the data of four metabolites 
(25(OH)D3, 3-epi-25(OH)D3, 1,25(OH)2D3, 24,25(OH)2D3) for a single and finding the best 
four-dimensional linear classifier increased the accuracy of distinguishing between PET and 
normal pregnancies to 74%, suggesting that measurement of multiple vitamin D metabolites 
has the potential to be a more accurate representation of vitamin D ‘status’. 
 
3.4 Strategy 2: Linear classifier analysis on metabolite ratios informed by the 
mathematical model 
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An alternative strategy to analyse serum vitamin D metabolite data in pregnancy is to 
consider metabolite ratios. Rather than calculating all possible combinations of vitamin D 
metabolites to form pairwise ratios, informative ratios, designated as  and  (Table 9), 
were determined directly from the steady state relationships outlined in the reduced kinetic 
model for vitamin D metabolism ((3.1b)-(3.1d), Table 8). 
 
Table 9. Summary of vitamin D metabolite ratios from the reduced kinetic model. 
Metabolite ratios defined from the reduced kinetic model (Figure 2) using steady state 
equations (Table 8).  Michaelis constants K are shown in nM and estimated value shown in 
Supplementary Table 4. Metabolites are listed with abbreviations in Table 3. 
 
 
(1α-hydroxylation) (3.2a) 
 
 
(epimerisation) (3.2b) 
 
(24-hydroxylation) (3.2c) 
 
Using the estimated Michaelis constant  (Supplementary Table 4) individual patient data 
were transformed (non-linearly) into three metabolite ratios (Table 9), reflecting the different 
major pathways in vitamin D metabolism. For example, rather than looking at isolated 3-epi-
25(OH)D3 values, the concentration of epimerised 25(OH)D3 in relation to 25(OH)D3 was 
considered, encoded by ratio ‘ ’. This approach appears more informative than interpretation 
of single 3-epi-25(OH)D3 concentrations which alone do not help explain whether an 
increased intake of 25(OH)D3 determines downstream vitamin D metabolite concentrations, 
or whether it is the epimerisation pathway that is specifically upregulated.  
The effect of transforming metabolite data into ratios before finding the best linear classifier 
was also assessed. This revealed significant improvement in the accuracy of classifiers. For 
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example, solely utilising the 3rd trimester epimerisation ratio (3.2b) as the linear classifier, 
results in an accuracy of 72% in delineating between healthy and PET pregnancies. 
Combining metabolite ratios together resulted in an accuracy of 84% for the West Midlands 
3rd trimester data. The high accuracy for the linear classifier based on the epimerisation 
ratio, β, alone suggests that changes in the vitamin D epimerisation pathway may be a 
marker of PET. Conversely, as illustrated in Figure 5, the combined metabolite ratio analysis 
did not improve the overall accuracy of classification in the 2nd trimester SCOPE data.  
  
A.  Classification accuracy based on 
metabolite concentrations  
(Strategy 1, Section 3.3) 
B. Classification accuracy based on 
metabolite ratios  
(Strategy 2, Section 3.4) 
Figure 5: Accuracy of best linear classifiers of data.  Accuracy classification is shown for 
2nd trimester (SCOPE) and 3rd trimester (West Midlands) data. A. Based on data for 
individual vitamin D metabolites, and combined vitamin D metabolites (diamonds). B. based 
on individual metabolite or combined metabolite ratios (diamonds). Reference baseline 
accuracy of 50% is indicated by dotted lines. 
 
4. Discussion 
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Vitamin D-deficiency has been linked to the pregnancy disorder PET, a condition that can 
increase morbidity and mortality in pregnant women, and their unborn and newborn babies. 
To date, studies of vitamin D and PET have focused on serum measurement of a single 
vitamin D metabolite, 25(OH)D3 despite the fact that pregnancy is characterised by distinct 
changes in vitamin D metabolism [29, 30]. The metabolic pathway for vitamin D is relatively 
well-defined and multiple vitamin D metabolites are measurable from serum. Using data from 
pregnant and non-pregnant women, where concentrations of four of these metabolites have 
been measured, the principal aim of this study was to use a combination of data analysis 
and mathematical modelling to identify differences in vitamin D metabolism between normal 
and PET pregnancies. In particular, the data from 2nd trimester pregnant women in the 
SCOPE study investigated to determine whether the models we used could accurately 
classify healthy normotensive (control) and PET (case) pregnant women prior to the onset of 
PET symptoms based upon early 2nd trimester vitamin D metabolite data.  
 
Mathematical modelling of metabolic networks can often lead to large numbers of ordinary 
differential equations governed by many parameters that are often neither measurable nor 
straightforward to estimate from experimental data. To address this, data from 3rd trimester 
pregnant women were utilised to develop a kinetic model of vitamin D metabolism 
incorporating 25(OH)D3, 3-epi-25(OH)D3, 1,25(OH)2D3 and 24,25(OH)2D3. From this we 
were able to reduce the full vitamin D network to include only these metabolites without 
disturbing the network shape surrounding them. In conjunction with literature values for half-
life times this facilitated full parametrisation of the ordinary differential equation model of the 
reduced vitamin D network, an achievement that is rare in related mathematical models. 
 
In the current study we compared two main modelling strategies, (i) linear classifier analysis 
using metabolite data and (ii) linear classifier analysis using metabolite ratios; the latter was 
motivated by analysis of our reduced kinetic model of vitamin D metabolism.  It was shown 
that this permits more accurate classification of trends in vitamin D metabolism in normal 
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and disease pregnancy compared to individual metabolite data analysis. Moreover, utilising 
combined metabolite ratios to reflect the interplay between the major metabolic pathways 
1α-hydroxylation, epimerisation and 24-hydroxylation, a more accurate classification of 3rd 
trimester healthy controls and PET cases was obtained.  
 
The high accuracy for the linear classifier based on the epimerisation ratio suggests changes 
in the epimerisation pathway of the vitamin D metabolism could be a marker of PET. Since 
this was only visible in the third trimester it appears changes in vitamin D metabolism are 
gradual and that significant dysregulation develops as a result of PET, rather than being a 
precursor to disease development, although it is important to recognise that the current 
study involved relatively small samples sizes.  
 
5. Summary and future work. The current study describes a novel strategy for 
understanding the differences in vitamin D metabolism between pregnant and non-pregnant 
women and distinguishing those pregnant women who have developed the pregnancy 
disorder PET. A major limitation of the current study was the small sample numbers in both 
the 2nd trimester (SCOPE) and 3rd trimester (West Midlands) studies. Future studies will aim 
to collect data from larger diverse cohorts of women to improve the reliability of both the 
statistical analyses and the model parametrisation described in the current mathematical 
analysis. The aim of mathematical modelling in this fashion is to generate new hypotheses 
for variations in vitamin D metabolism during pregnancy. In turn this may help to identify 
novel intervention and supplementation strategies for both normal pregnancy and PET. 
However, the potential applications for this mathematical modelling strategy extend far 
beyond pregnancy, with clear opportunities for refining our overall approach to the 
assessment of vitamin D related health and disease.  
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